Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PDE5A | O76074 | 8/20 | 0.51 |
| ▸ | GUCY1A1 | Q02108 | 10/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 10/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14362934 | 0.93 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14362940 | 0.93 | ADORA3 (0.58) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL5471729 | 0.93 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL5475579 | 0.91 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL175344 | 0.88 | ADORA3 (0.63) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14362979 | 0.86 | ADORA3 (0.52) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14362950 | 0.85 | ADORA3 (0.71) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL5468137 | 0.85 | ADORA3 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14362972 | 0.84 | PDE5A (0.51) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL5477476 | 0.84 | ADORA3 (0.67) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291622-B2 | Medical uses of carbamate-substituted pyrazolo-pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291622-B2 | Medical uses of carbamate-substituted pyrazolo-pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291622-B2 | Medical uses of carbamate-substituted pyrazolo-pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7105523-B2 | Carbamate-substituted pyrazolopyridine-derivatives | BAYER AKTIENGESELISCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050261323-A1 | Medical uses of novel carbamate-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | GPR3, NOS3, NPR3 | ADORA3 160/4885KCNH2 200/4885PDE5A 28/4885 |
| US-20050261323-A1 | Medical uses of novel carbamate-substituted pyrazolopyridine derivatives | NOS3, NOX3, NPR3 | ADORA3 107/4885KCNH2 618/4885PDE5A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.